Rapidly progressive cognitive decline associated with teprotumumab in thyroid eye disease

Teprotumumab (Tepezza), an insulin-like growth factor type 1 receptor antagonist, was approved for treatment of thyroid eye disease in 2020. Teprotumumab is administered intravenously every 3 weeks for a total of eight doses. Common side effects include nausea, diarrhoea, muscle spasms, hearing impa...

Descripción completa

Detalles Bibliográficos
Autores principales: Hoang, Thanh Duc, Nguyen, Nguyen T, Chou, Eva, Shakir, Mohamed KM
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8112427/
https://www.ncbi.nlm.nih.gov/pubmed/33972303
http://dx.doi.org/10.1136/bcr-2021-242153

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8112427/
https://www.ncbi.nlm.nih.gov/pubmed/33972303
http://dx.doi.org/10.1136/bcr-2021-242153

Ejemplares similares